1
|
Mamand DR, Bazaz S, Mohammad DK, Saher O, Wiklander OPB, Sadeghi B, Hassan M, El-Andaloussi S, Abedi-Valugerdi M. Tumor cell derived osteopontin and prostaglandin E2 synergistically promote the expansion of myeloid derived suppressor cells during the tumor immune escape phase. Int Immunopharmacol 2024; 129:111584. [PMID: 38364741 DOI: 10.1016/j.intimp.2024.111584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Revised: 01/09/2024] [Accepted: 01/22/2024] [Indexed: 02/18/2024]
Abstract
The immune escape stage in cancer immunoediting is a pivotal feature, transitioning immune-controlled tumor dormancy to progression, and augmenting invasion and metastasis. Tumors employ diverse mechanisms for immune escape, with generating immunosuppressive cells from skewed hematopoiesis being a crucial mechanism. This led us to suggest that tumor cells with immune escape properties produce factors that induce dysregulations in hematopoiesis. In support of this suggestion, this study found that mice bearing advanced-stage tumors exhibited dysregulated hematopoiesis characterized by the development of splenomegaly, anemia, extramedullary hematopoiesis, production of immunosuppressive mediators, and expanded medullary myelopoiesis. Further ex vivo studies exhibited that conditioned medium derived from EL4lu2 cells could mediate the expansion of myeloid derived suppressor cells (MDSCs) in bone marrow cell cultures. The protein array profiling results revealed the presence of elevated levels of osteopontin (OPN), prostaglandin E2 (PGE2) and interleukin 17 (IL-17) in the culture medium derived from EL4luc2 cells. Accordingly, substantial levels of these factors were also detected in the sera of mice bearing EL4luc2 tumors. Among these factors, only PGE2 alone could increase the number of MDSCs in the BM cell cultures. This effect of PGE2 was significantly potentiated by the presence of OPN but not IL-17. Finally, in vitro treatment of EL4luc2 cells with pioglitazone, a modulator of OPN and cyclooxygenase 2 (COX-2) resulted in a significant reduction in cell proliferation in EL4luc2 cells. Our findings highlight the significant role played by tumor cell-derived OPN and PGE2 in fostering the expansion of medullary MDSCs and in promoting tumor cell proliferation. Furthermore, these intertwined cancer processes could be key targets for pioglitazone intervention.
Collapse
Affiliation(s)
- Doste R Mamand
- Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden
| | - Safa Bazaz
- Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden
| | - Dara K Mohammad
- Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, SE-141 83 Stockholm, Sweden; College of Agricultural Engineering Sciences, Salahaddin University-Erbil, Kurdistan Region, Erbil 44002, Iraq
| | - Osama Saher
- Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt
| | - Oscar P B Wiklander
- Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden
| | - Behnam Sadeghi
- Translational Cell Therapy Research (TCR), Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Moustapha Hassan
- Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Experimental Cancer Medicine, Karolinska Institutet and Karolinska University Hospital, Huddinge, Sweden
| | - Samir El-Andaloussi
- Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden
| | - Manuchehr Abedi-Valugerdi
- Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
| |
Collapse
|
2
|
Huang CY, Wu XB. Pembrolizumab plus chemotherapy for advanced gastric cancer. Lancet Oncol 2024; 25:e50. [PMID: 38301692 DOI: 10.1016/s1470-2045(23)00573-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Revised: 10/31/2023] [Accepted: 10/31/2023] [Indexed: 02/03/2024]
Affiliation(s)
- Chen-Yu Huang
- Department of Gastrointestinal Surgery, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, and The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510150, China
| | - Xiao-Bing Wu
- Department of Gastrointestinal Surgery, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, and The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510150, China.
| |
Collapse
|
3
|
Tellez RSL, Reynolds L, Piris MA. Myeloid-derived suppressor cells (MDSCs): what do we currently know about the effect they have against anti-PD-1/PD-L1 therapies? Ecancermedicalscience 2023; 17:1556. [PMID: 37396098 PMCID: PMC10310335 DOI: 10.3332/ecancer.2023.1556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Indexed: 07/04/2023] Open
Abstract
Recent advances in cancer treatment such as PD-1/PD-L1 checkpoint inhibitors have prompted multiple research studies to determine all of the factors that influence response or failure to these new treatments. One of those identified factors is myeloid-derived suppressor cells (MDSCs). These cells were identified and described for the first time in 2007 in laboratory mice and cancer patients. Previous studies showed that a greater number of MDSCs was directly related to a greater tumour volume. There are two clearly identified subpopulations: Mononuclear-type myeloid-derived suppressor cells (M-MDSCs) and polymorphonuclear (PMN-MDSCs). These cell population subtypes play a very important role, depending on the type of cancer, since they have the particularity of expressing PD-L1, which interacts with PD-1, inhibiting the expansion of cytotoxic T lymphocytes, promoting resistance to these treatments.
Collapse
Affiliation(s)
- Ronald Sergio Limón Tellez
- Department of Oncology, University Social Security USS, Nº58 Colon Street, 10260 Santa Cruz, Bolivia
- Associate Medical Oncology and Research, OncoBolivia Specialized Center for Cancer Treatment, Nº236 Azucenas Street, Equipetrol, Santa Cruz, Bolivia
- Department of Oncology and Research, Clinic of The Americas, Nº5001 Sixth Ring Avenue and Beni Street, 10260 Santa Cruz, Bolivia
- Associate Medical Chief Pathology Service, Fundación Jiménez Diaz, Nº228040 Reyes Católicos Avenue, 2552 Madrid, España
| | - Lucia Reynolds
- Associate Medical Oncology and Research, OncoBolivia Specialized Center for Cancer Treatment, Nº236 Azucenas Street, Equipetrol, Santa Cruz, Bolivia
- Department of Oncology and Research, Clinic of The Americas, Nº5001 Sixth Ring Avenue and Beni Street, 10260 Santa Cruz, Bolivia
| | - Miguel A Piris
- Associate Medical Chief Pathology Service, Fundación Jiménez Diaz, Nº228040 Reyes Católicos Avenue, 2552 Madrid, España
| |
Collapse
|
4
|
Mathew AA, Zakkariya ZT, Ashokan A, Manohar M, Keechilat P, Nair SV, Koyakutty M. 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor. Int Immunopharmacol 2023; 120:110129. [PMID: 37201402 DOI: 10.1016/j.intimp.2023.110129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Revised: 03/22/2023] [Accepted: 03/29/2023] [Indexed: 05/20/2023]
Abstract
Tumor microenvironment (TME) is a heterogeneous system consisting of both cellular and acellular components. The growth and progression of tumors rely greatly on the nature of TME, marking it as an important target in cancer immunotherapy. Lewis Lung Carcinoma (LLC) is an established murine lung cancer model representing immunologically 'cold' tumors characterized by very few infiltrated cytotoxic T-cells, high levels of Myeloid-Derived Suppressor Cells (MDSCs) and Tumor-Associated Macrophages (TAMs). Here, we report various strategies we applied to reverse the non-immunogenic character of this cold tumor by imparting: a) immunogenic cell death using Hypericin nanoparticle-based photodynamic therapy (PDT), b) repolarising TAM using a TLR7/8 agonist, resiquimod, c) immune checkpoint inhibition using anti-PD-L1 and d) depleting MDSCs using low-dose 5-fluorouracil (5-FU) chemotherapy. Interestingly, the nano-PDT, resiquimod or anti-PD-L1 treatment had no major impact on tumor growth, whereas low-dose 5-FU-mediated depletion of MDSCs showed significant anti-tumor effect, primarily caused by the increased infiltration of CD8+ cytotoxic T-cells (∼96%). Though we have tested combining PDT with resiquimod or 5-FU for any synergistic effect, low-dose 5-FU alone showed better response than combinations. In effect, we show that depletion of MDSCs using low-dose 5-FU was one of the best methods to augment infiltration of CD8+ cytotoxic T-cells into a cold tumor, which is resistant to conventional therapies including immune checkpoint inhibitors.
Collapse
Affiliation(s)
- Ambily Anna Mathew
- Amrita School of Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India
| | - Zahara T Zakkariya
- Amrita School of Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India
| | - Anusha Ashokan
- Amrita School of Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India
| | - Maneesh Manohar
- Amrita School of Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India
| | - Pavithran Keechilat
- Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India
| | - Shantikumar V Nair
- Amrita School of Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India
| | - Manzoor Koyakutty
- Amrita School of Nanosciences and Molecular Medicine, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India.
| |
Collapse
|
5
|
Papafragkos I, Markaki E, Kalpadakis C, Verginis P. Decoding the Myeloid-Derived Suppressor Cells in Lymphoid Malignancies. J Clin Med 2021; 10:jcm10163462. [PMID: 34441758 PMCID: PMC8397155 DOI: 10.3390/jcm10163462] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 07/21/2021] [Accepted: 07/22/2021] [Indexed: 12/12/2022] Open
Abstract
Myeloid-derived suppressor cells (MDSCs) are immature myeloid precursors which emerged as a potent regulator of the immune system, exerting suppressive properties in diverse disease settings. In regards to cancer, MDSCs have an established role in solid tumors; however, their contribution to immune regulation during hematologic malignancies and particularly in lymphomas remains ill-defined. Herein focused on lymphoma, we discuss the literature on MDSC cells in all histologic types, and we also refer to lessons learned by animal models of lymphoma. Furthermore, we elaborate on future directions and unmet needs and challenges in the MDSC field related to lymphoma malignancies which may shed light on the complex nature of the immune system in malignancies.
Collapse
Affiliation(s)
- Iosif Papafragkos
- Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Medical School, University of Crete, 71003 Heraklion, Greece; (I.P.); (E.M.)
| | - Efrosyni Markaki
- Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Medical School, University of Crete, 71003 Heraklion, Greece; (I.P.); (E.M.)
| | - Christina Kalpadakis
- Laboratory of Haematology, Division of Laboratory Medicine, Medical School, University of Crete, 71003 Heraklion, Greece
- Department of Laboratory Haematology, University Hospital of Heraklion, 71500 Heraklion, Greece
- Correspondence: (C.K.); (P.V.); Tel.: +30-69-4458-2738 (C.K.); +30-28-1039-4553 (P.V.)
| | - Panayotis Verginis
- Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Medical School, University of Crete, 71003 Heraklion, Greece; (I.P.); (E.M.)
- Department of Laboratory Haematology, University Hospital of Heraklion, 71500 Heraklion, Greece
- Correspondence: (C.K.); (P.V.); Tel.: +30-69-4458-2738 (C.K.); +30-28-1039-4553 (P.V.)
| |
Collapse
|
6
|
Navashenaq JG, Zamani P, Nikpoor AR, Tavakkol-Afshari J, Jaafari MR. Doxil chemotherapy plus liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast cancer. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2020; 24:102150. [PMID: 31931230 DOI: 10.1016/j.nano.2020.102150] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 12/22/2019] [Accepted: 12/23/2019] [Indexed: 12/15/2022]
Abstract
Myeloid-derived suppressor cells (MDSCs) play a pivotal role in cancer. To overcome the problem of the MDSCs in the tumor microenvironment in this study, a combination of immunotherapy and chemotherapy was used. For this purpose, a liposomal formulation of P5 peptide and PEGylated liposomal doxorubicin (Doxil®) was utilized to treat mice bearing HER2+ tumor model. The results revealed that Doxil® administration before immunotherapy had not only reduced the population and functions of the MDSCs in the spleen (P < 0.001) and the tumor microenvironment (P < 0.05) but had also supported further immunotherapy including enhanced CD4+ (P < 0.01) and CD8+ lymphocyte (P < 0.001) population and IFN-γ production (P < 0.001). This effect was also more pronounced with a liposomal P5 and Doxil® compared with free peptide and doxorubicin. In conclusion, the results demonstrated that Doxil® plus liposomal P5 could have a decreasing effect on MDSCs and tumor growth, and it could be beneficial in breast cancer treatment.
Collapse
Affiliation(s)
- Jamshid Gholizadeh Navashenaq
- Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Immunology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Parvin Zamani
- Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Amin Reza Nikpoor
- Department of Immunology, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
| | | | - Mahmoud Reza Jaafari
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
7
|
Du J, Dong W, Li H, Li B, Liu X, Kong Q, Sun W, Sun T, Ma P, Cui Y, Kang P. Protective effects of IFN-γ on the kidney of type- 2 diabetic KKAy mice. Pharmacol Rep 2017; 70:607-613. [PMID: 29684848 DOI: 10.1016/j.pharep.2017.12.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Revised: 12/19/2017] [Accepted: 12/20/2017] [Indexed: 12/19/2022]
Abstract
BACKGROUND Development of novel therapeutic strategies that specifically target diabetic kidney disease (DKD) is urgently needed. METHODS Male KKAy mice were divided randomly into three equal groups - KK, KI, and KF; Male C57BL/6 mice were the control group. All KKAy mice were fed a high-fat diet. From the 16th week, the KI group was given IFN-γ, and the KF group was assigned to be treated with fludarabine. C57BL/6 mice were always fed a normal mouse diet. Every 4 weeks, body weight, random blood sugar, urine albumin and urea of all mice were measured. At the 20th week, all mice were killed, renal tissue was obtained to observe the pathological manifestations and extract proteins, and transforming growth factor- beta1 (TGF-β1), collagen IV and Janus kinase 2/signal transducers and activators of transcription 1 (JAK2/STAT1) pathway proteins were measured by western blot. RESULTS The present study showed that all KKAy mice appeared obese and hyperglycaemic from 12 weeks old and exhibited an increased urine albumin-to-creatinine ratio (ACR) from 16 weeks old. At the 20th week, compared to the KK group, the KI group showed lower ACR, more overexpression of P-STAT1 and less expression of TGF-β1 and collagen IV proteins in renal tissue. The KI group mice showed less accumulation of glomerular mesangial matrix than those in the KK group. CONCLUSIONS Our results indicate that IFN-γ might activate STAT1 to suppress the overexpression of TGF-β1 and collagen IV proteins and attenuate the excessive accumulation of mesangial matrix under DKD conditions in KKAy mice.
Collapse
Affiliation(s)
- Juan Du
- Department of Nephrology, Daqing Oilfield General Hospital, Daqing, PR China.
| | - Wenpeng Dong
- Department of Nephrology, Daqing Oilfield General Hospital, Daqing, PR China.
| | - Huifeng Li
- Department of Nephrology, Daqing Oilfield General Hospital, Daqing, PR China.
| | - Bo Li
- Department of Nephrology, Daqing Oilfield General Hospital, Daqing, PR China.
| | - Xiaodan Liu
- Department of Nephrology, First Hospital of China Medical University, Shenyang, PR China.
| | - Qinghui Kong
- Daqing OilField Communication Technology Company, Daqing, PR China.
| | - Wei Sun
- Department of Nephrology, Daqing Oilfield General Hospital, Daqing, PR China.
| | - Tingli Sun
- Department of Nephrology, Daqing Oilfield General Hospital, Daqing, PR China.
| | - Peilong Ma
- Department of Nephrology, Daqing Oilfield General Hospital, Daqing, PR China.
| | - Yan Cui
- Department of Nephrology, Daqing Oilfield General Hospital, Daqing, PR China.
| | - Ping Kang
- Department of Nephrology, Daqing Oilfield General Hospital, Daqing, PR China.
| |
Collapse
|
8
|
Liu Z, Xie W, Li M, Teng N, Liang X, Zhang Z, Yang Z, Wang X. Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. Basic Clin Pharmacol Toxicol 2017; 121:480-486. [PMID: 28667794 DOI: 10.1111/bcpt.12841] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Accepted: 06/22/2017] [Indexed: 12/17/2022]
Affiliation(s)
- Zhaoyang Liu
- Tumor Marker Research Center; National Cancer Center/Cancer Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing China
| | - Wenbo Xie
- Jilin Province Broadwell Pharmaceutical Co., Ltd.; Changchun China
| | - Mingru Li
- Jilin Province Broadwell Pharmaceutical Co., Ltd.; Changchun China
| | - Nan Teng
- Jilin Province Broadwell Pharmaceutical Co., Ltd.; Changchun China
| | - Xiao Liang
- State Key Laboratory of Molecular Oncology; National Cancer Center/Cancer Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing China
| | - Ziqiang Zhang
- State Key Laboratory of Molecular Oncology; National Cancer Center/Cancer Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing China
| | - Zhaogang Yang
- NSF Nanoscale Science and Engineering Center (NSEC); The Ohio State University; Columbus OH USA
| | - Xiaobing Wang
- Tumor Marker Research Center; National Cancer Center/Cancer Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing China
| |
Collapse
|